

Notification 6589

<u>Category</u> <u>HCPCS - Drugs & Biologicals</u>

Topic

Louisiana Medicaid - tocilizumab, 1 mg

What is changing?

We limit reimbursement of charges for tocilizumab, 1 mg, to no more than 5,600 units every 26 weeks if the diagnosis on the claim is any of the following:

- Giant cell arteritis
- Immune checkpoint inhibitor-related toxicity (giant cell arteritis)
- Immune checkpoint inhibitor-related toxicity (reactive arthropathy)
- Rheumatoid arthritis

Language

English

Impacted Products

Medicaid – Louisiana

Why is Humana making this change?

The above limitations were established by the FDA-approved package insert and prescribing information and pharmaceutical compendia for tocilizumab, 1 mg.Note: The limitations described above are based on maximum dosages established in milligrams. If any units are denied, the provider may dispute and submit information, including medical notes showing the patient's body weight, that substantiates the medical necessity of the additional units.